Minimally invasive surgical management of primary venous ulcers vs. compression treatment: a randomized clinical trial

n/

Influenza vaccination among the elderly according to place of residence: prevalence and associated factors

Influenza vaccination is the main means of preventing and reducing morbidity and mortality associated with this disease among the elderly population. The aim of the present study is to determine demographic, socioeconomic, behavioral, and health-related factors associated with vaccination among the elderly living in different areas of the State of Sao Paulo, in the 2001-2002 period. It is a cross-sectional population-based study including elderly subjects living in two areas of the State: one comprises the municipality of Campinas and the Butantã district in the City of São Paulo, and another comprises the municipalities of Taboão da Serra, Embu, and Itapecerica da Serra (metropolitan area of the City of Sao Paulo). The samples included 849 and 641 subjects, aged 60 years or older living in the two areas, respectively. Crude analysis was carried out using prevalence ratios and 95% confidence intervals. Multiple analysis was performed by Poisson regression. The prevalence of self-reported vaccination was 66.9% among residents of Campinas and in the Butantã district, and 67.6% among residents of the remaining cities. After adjusted analysis, among the subjects living in Campinas and in the Butantã district, only lesser schooling (PR = 1.25; 95%CI: 1.02-1.54) was associated with vaccination. In the group comprising the less densely populated municipalities, older age (PR = 1.15; 95%CI: 1.02-1.31), and reported hypertension (PR = 1.21; 95%CI: 1.02-1.45), diabetes (PR = 1.16; 95%CI: 1.01-1.33), and chronic pulmonary disease (PR = 1.30; 95%CI: 1.03-1.64) were also associated with the outcome. Despite the prevalence of influenza vaccination among the elderly populations in the different areas being practically identical, we found differences in the profile of elderly individuals with respect to reported vaccination.A vacinação contra influenza é a principal forma de prevenir e reduzir a morbidade e mortalidade associadas à doença entre os idosos e grupos de risco. O objetivo deste estudo é determinar fatores demográficos, socioeconômicos, comportamentais e de saúde associados à vacinação, entre idosos residentes em diferentes áreas do Estado de São Paulo, no período de 2001 a 2002. Trata-se de um delineamento transversal de base populacional que considerou os idosos residentes em duas áreas do Estado: uma composta pelo município de Campinas e distrito do Butantã, na cidade de São Paulo, e outra pelos municípios de Taboão da Serra, Embu e Itapecerica da Serra (região metropolitana do município de São Paulo). A amostra foi composta por 849 e 641 indivíduos com 60 anos ou mais, residentes em tais localidades, respectivamente. Na análise bruta foram utilizadas razões de prevalência e intervalos de confiança de 95% e a análise multivariada foi realizada pela regressão de Poisson. A prevalência de vacinação auto-referida foi de 66,9% entre os residentes em Campinas e no distrito do Butantã e 67,6% naqueles das demais localidades. Após análise ajustada, para os idosos de Campinas e Butantã, apenas menor escolaridade (RP = 1,25; IC 95%: 1,02-1,54) esteve associada à vacinação. Já na área composta pelos municípios menos populosos, idade mais avançada (RP = 1,15; IC 95%: 1,02-1,31), hipertensão arterial (RP = 1,21; IC 95%: 1,02-1,45), diabetes (RP = 1,16; IC 95%: 1,01-1,33) e doença crônica de pulmão (RP = 1,30; IC 95%: 1,03-1,64) referidas, estiveram também associadas. Apesar de a prevalência de vacinação contra influenza entre os idosos das diversas localidades ser praticamente a mesma, pôde-se observar diferenças no perfil do idoso quanto à referência desse procedimento preventivo.16217

Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial

Background: This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy of locally advanced rectal cancer.Patients and methods: The PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter study aimed at evaluating the efficacy and safety of preoperative treatment with durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2 twice daily). The primary endpoint was the pathological complete response (pCR) rate; secondary endpoints were the proportion of clinical complete remissions and safety. The sample size was estimated assuming a null pCR proportion of 0.15 and an alternative pCR proportion of 0.30 (a = 0.05, power = 0.80). The proposed treatment could be considered promising if >= 13 pCRs were observed in 55 patients (EudraCT: 2018-004758-39; NCT04083365).Results: Between November 2019 and August 2021, 60 patients were accrued, of which 55 were assessable for the study's objectives. Two patients experienced disease progression during treatment. Nineteen out of 55 eligible patients achieved a pCR (34.5%, 95% confidence interval 22.2% to 48.6%). Regarding toxicity related to durvalumab, grade 3 adverse events (AEs) occurred in four patients (7.3%) (diarrhea, skin toxicity, transaminase increase, lipase increase, and pancolitis). Grade 4 toxicity was not observed. In 20 patients (36.4%), grade 1-2 AEs related to durvalumab were observed. The most common were endocrine toxicity (hyper/hypothyroidism), dermatologic toxicity (skin rash), and gastrointestinal toxicity (transaminase increase, nausea, diarrhea, constipation).Conclusion: This study met its primary endpoint showing that CRT followed by durvalumab could increase pCR with a safe toxicity profile. This combination is a promising, feasible strategy worthy of further investigation

Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy

Background: Despite the well-known efficacy of anti-COVID-19 vaccines in preventing morbidity and mortality, several vaccinated individuals are diagnosed with SARS-CoV-2 breakthrough infection, which might require hospitalisation. This multicentre, observational, and retrospective study aimed to investigate the clinical characteristics and outcomes of vaccinated vs. non -vaccinated patients, both hospitalised with SARS-CoV-2 infection in 3 major hospitals in Northern Italy. Methods: Data collection was retrospective, and paper and electronic medical records of adult patients with a diagnosed SARS-CoV-2 infection were pseudo-anonymised and analysed. Vaccinated and non -vaccinated individuals were manually paired, using a predetermined matching criterion (similar age, gender, and date of hospitalisation). Demographic, clinical, treatment, and outcome data were compared between groups differing by vaccination status using Pearson's Chi-square and Mann -Whitney tests. Moreover, multiple logistic regression analyses were performed to assess the impact of vaccination status on ICU admission or intra-hospital mortality. Results: Data from 360 patients were collected. Vaccinated patients presented with a higher prevalence of relevant comorbidities, like kidney replacement therapy or haematological malignancy, despite a milder clinical presentation at the first evaluation. Non -vaccinated patients required intensive care more often than their vaccinated counterparts (8.8% vs. 1.7%, p = 0.002). Contrariwise, no difference in intra-hospital mortality was observed between the two groups (19% vs. 20%, p = 0.853). These results were confirmed by multivariable logistic regressions, which showed that vaccination was significantly associated with decreased risk of ICU admission (aOR=0.172, 95%CI: 0.039-0.542, p = 0.007), but not of intra-hospital mortality (aOR=0.996, 95%CI: 0.582-1.703, p = 0.987). Conclusions: This study provides real -world data on vaccinated patients hospitalised with COVID-19 in Northern Italy. Our results suggest that COVID-19 vaccination has a protective role in individuals with higher risk profiles, especially regarding the need for ICU admission. These findings contribute to our understanding of SARS-CoV-2 infection outcomes among vaccinated individuals and emphasise the importance of vaccination in preventing severe disease, particularly in those countries with lower first -booster uptake rates